The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Alzheimer's disease (AD) is a rapidly growing disease that is estimated to affect about 36 million people worldwide, therefore there is an immediate need for its' early diagnosis and treatment. A number of research studies are performed on possible accurate and reliable diagnostic biomarkers of AD. This review study provides an update on the cerebrospinal fluid (CSF) proteins that are being currently used in clinical practice and studied as biomarkers for early AD diagnosis and their future prospects, as well as relevant patents.

Event-related potentials for the diagnosis of mild cognitive impairment and Alzheimer's disease.

Introduction: Alzheimer's disease (AD) and the nosological entity of mild cognitive impairment (MCI) constitute a major public health concern. The diagnostic approach and therapeutic management of these disorders may be significantly improved by recent advances in the field of event-related potentials (ERPs).

Areas Covered: The authors performed a PubMed search in order to identify full-length, original research articles on the experimental and clinical application of ERPs in AD and MCI.

Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease.

Alzheimer's disease (AD) is rapidly grooving incidence that affects millions of people worldwide, therefore there is an immediate need for its' early and accurate diagnosis. Many research studies have been performed on possible accurate and reliable diagnostic biomarkers of AD. This review study provides an overview on the cerebrospinal fluid (CSF) proteins that are used as biochemical markers for the early diagnosis of AD and their future prospects, as well as relevant patents.

Male patient with mild cognitive impairment and extremely high P300 and Slow-wave latencies: a case report.

We present a case of a 74-year-old Greek male who suffered from paraphasias, memory and orientation problems. The patient was assessed with neuropsychometric tests, auditory event-related potentials and cerebrospinal fluid proteins and was diagnosed with mild cognitive impairment. The emphasis on the case is on the unexplained high levels of P300 and Slow wave of the auditory event-related potentials.

Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.

Background/aims: The aim of this study was to investigate the role of cerebrospinal fluid beta-amyloid(1-42) levels and auditory event-related potentials (AERPs) in the progress of mild cognitive impairment (MCI) to Alzheimer's disease (AD).

Methods: In 53 MCI patients, lumbar puncture was performed and beta-amyloid(1-42) levels were determined. Twenty patients were reexamined after 11 months.